2015 Therapeutic Proteins

Critical facts iconCRITICAL FACTS:
(if med school is a Minnesota forest with millions of trees, these are the red pines)

  1. One of the most rapidly expanding areas of pharmacology is the use of therapeutic proteins.  In particular, antibodies are receiving considerable attention as “personalized” therapies, because of their specificity and the large number of potential targets.

  2. In addition to their specificity, one advantage of monoclonal antibodies is their long half-life.  Their major drawback is hypersensitivity reactions, in particular human antimouse antibody (“HAMA”) reactions.

  3. The major disadvantages to cytokine therapy are the extremely short half-lives of the drugs and the complicated nature of the biological response typically invoked by administration of these agents.

  4. Bone marrow suppression is the dose-limiting complication of many antineoplastic drugs, and recombinant forms of several colony stimulating factors have been developed to combat this problem.  These factors activate specific progenitor cells, resulting in the production of:  ERYTHROPOIETIN → red blood cells, FILGRASTIM (G-CSF) → neutrophils, SAGRAMOSTIM (GM-CSF) → granulocytes, eosinophils, basophils and monocytes and INTERLEUKIN 11 and ROMIPLOSTIM → platelets.

Email: Dr. Janet Fitzakerley | ©2015 University of Minnesota Medical School Duluth | Last modified: 27-apr-15 1:11 PM